OncoSignal

David Apelian

Eiger BioPharmaceuticals

Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.

Registry trials as an overall official
1
all conditions, ClinicalTrials.gov
NIH grants tied to them
0
NIH RePORTER
Trial papers
6
PubMed author-name match

Trials

Studies that name David Apelian as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:45 UTC. Open this list on ClinicalTrials.gov

Grants

NIH projects from RePORTER, fetched 2026-11-12 01:45 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

Most cited trial papers

Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:45 UTC. The ranking covers the 200 most relevant of 6 PubMed records, and a shared surname and initials can bring in a namesake. All 6 on PubMed

  1. 1,131 citations
    RCR 29.6
  2. 82 citations
    RCR 2.6
  3. 78 citations
    RCR 2.2
  4. 63 citations
    RCR 1.4
  5. 61 citations
    RCR 4.8
  6. 36 citations
    RCR 1.1